Pramipexole dihydrochloride monohydrate Chemical Properties

Melting point:

290 °C(dec.)

storage temp. 

2-8°C

solubility 

Freely soluble in water, soluble in methanol, sparingly soluble or slightly soluble in ethanol (96 per cent), practically insoluble in methylene chloride.

color 

White to Almost white

Merck 

14,7705

BCS Class

1

InChI

InChI=1/C10H17N3S.ClH.H2O/c1-2-5-12-7-3-4-8-9(6-7)14-10(11)13-8;;/h7,12H,2-6H2,1H3,(H2,11,13);1H;1H2/t7-;;/s3

InChIKey

ZTZQAWQFTIVKMU-DCFBZVEJNA-N

SMILES

NC1SC2C[C@@H](NCCC)CCC=2N=1.Cl.O |&1:5,r|

Safety Information

WGK Germany 

3

RTECS 

DL3375000

HS Code 

2934200000

Pramipexole dihydrochloride monohydrate Usage And Synthesis

Description

Pramipexole dihydrochloride monohydrate is an activator of D2DR, D3DR and D4DR. Pramipexole has been found to have neuroprotective effects independent of its dopamine receptor agonism. It reduces mitochondrial reactive oxygen species (ROS) production and inhibits the activation of apoptotic pathways.

Chemical Properties

White or almost white, crystalline powder.

Uses

Pramipexole is a drug used to treat the symptoms of Parkinson's Disease (PD) and a antidepressant. It is a non-ergot dopamine agonist drug that is efficacious in treating various Parkinson's symptoms such as tremor, rigidity, and bradykinesia (slow movement)

Definition

ChEBI: A hydrate that is the monohydrate of the dihydrochloride salt of pramiprexole.

brand name

Mirapex (Boehringer Ingelheim).

General Description

Pramipexole Dihydrochloride is a non-ergot dopamine agonist widely used for the treatment of early and advanced Parkinson′s disease (PD). It is also used to treat restless legs syndrome.
Pharmaceutical secondary standards for application in quality control, provide pharma laboratories and manufacturers with a convenient and cost-effective alternative to the preparation of in-house working standards.

Clinical Use

Parkinson’s disease

Symptomatic treatment of restless legs

Side effects

Dizziness, lightheadedness, or fainting, especially when standing up suddenly from a sitting/lying position.
drowsiness.
nausea.
seeing, hearing, or feeling things that are not there.
trouble sleeping.
twitching, twisting, or other unusual body movements.
unusual tiredness or weakness.

Drug interactions

Potentially hazardous interactions with other drugs
Avoid concomitant use with antipsychotics.

Metabolism

Pramipexole undergoes <10% metabolism to inactive metabolites.
More than 90% of a dose is excreted via renal tubular secretion unchanged into the urine.

Pramipexole dihydrochloride monohydrate(191217-81-9)Related Product Information

• HYDRAZINE
• Tris(hydroxymethyl)aminomethane
• PRAMIPEXOLE DIHYDROCHLORIDE,PRAMIPEXOLE HYDROCHLORIDE,PRAMIPEXOLE HCL
• Propranolol hydrochloride
• Propafenone Hydrochloride
• Lithium diisopropylamide
• ALTRENOGEST
• Benzothiazole
• 2-Mercaptobenzothiazole
• Chloral hydrate
• Propyl butyrate
• 2,2'-Dithiobis(benzothiazole)
• Glycine
• Propyl gallate
• 6-Aminocaproic acid
• D-Glucosamine hydrochloride
• Dihydrochloride
• PRAMIPEXOLE: PRAMIPEXOLE DIHYDROCHLORIDE,PRAMIPEXOLE 2HCL MONOHYDRATE,Pramipexole